SUPARTZ®

SUPARTZ® is an injectable hyaluronic acid (HA) viscosupplement used for the treatment of osteoarthritis-related knee pain. It contains high-purity sodium hyaluronate derived from a natural, non-animal source and is designed to mimic the properties of healthy synovial fluid in the knee joint.

When injected directly into the synovial cavity, SUPARTZ® restores the viscoelasticity of joint fluid, reducing friction between the cartilage surfaces. It provides mechanical support, improves shock absorption, and alleviates pain by enhancing the lubrication within the joint environment. Additionally, it may slow the progression of cartilage degradation by supporting joint function over time.

SUPARTZ® is primarily used to manage symptoms of knee osteoarthritis. It is indicated for:

• Patients experiencing persistent knee pain unresponsive to conservative treatment 
• Restoring joint lubrication and improving mobility 
• Reducing dependency on systemic pain medications or anti-inflammatory drugs 
• Delaying the need for surgical intervention or joint replacement 

Its ability to simulate natural synovial fluid makes SUPARTZ® a preferred option in non-surgical osteoarthritis management.

SUPARTZ® is a globally recognized viscosupplement backed by clinical studies and a long-standing track record in orthopedic care. It is widely used by healthcare professionals for its consistency, safety, and efficacy.

Key benefits of choosing SUPARTZ®:

• Formulated with ultra-pure, non-animal sodium hyaluronate 
• High molecular weight HA for enhanced durability and joint performance 
• Well tolerated with minimal risk of immunogenic response 
• Supported by multiple international regulatory approvals 
• Trusted in over 30 countries for more than two decades 

For clinicians looking to buy SUPARTZ injections as a reliable option in osteoarthritis treatment protocols, it offers a balance of safety, patient comfort, and therapeutic longevity.

SUPARTZ® is typically administered as a course of three to five weekly injections, although regimens may vary depending on the product variant and clinical judgment.

Pain relief may begin within days of the first injection, with optimal results achieved within several weeks. Clinical effects can last up to six months, and some patients report extended improvement in joint mobility and pain reduction beyond this period.

SUPARTZ® has an established safety profile. Its formulation is non-animal derived and manufactured under sterile, controlled conditions. Adverse reactions are rare and generally mild when administered properly.

Typical safety considerations:

• Well tolerated by most patients 
• No known systemic interactions with other medications 
• Minimal risk of allergic response 
• Approved for intra-articular use under medical supervision 

It is important that SUPARTZ® be administered only by qualified healthcare providers trained in joint injection techniques.